Your dance partner suggestion is the best case scenario but when it comes to push or shove and we need to move forward on Nash and any other trial that is close or closer to a guaranteed approval. I am willing to vote my shares for the money/shares needed to get us there at the next shareholders meeting. I don’t want to do this and hate dilution but if we don’t acquire the dance partner to take the load off of our potential dilution then that is our only option moving forward. We might want to study this option.

And I want to move forward and not backwards. So funding this company anyway possible to approval is what we will have to do. It’s not a matter if we want to… it’s a matter of what we might just have to do. So we should be prepared to talk about it at some point. Nobody likes dilution. But options are just that and we have enough shares to get us to the shareholders meeting and more shares to be authorized if need be.

What was the average of a drug to market? 12 years and 2 billion shares? We have only authorized half of the average and are at under 10 years. So our time is coming. What is better for our investment? A partner for half of our profits (if we are lucky) or authorizing more shares to get us to an approval? These are the things we should be discussing as our future is uncharted with no CEO and current leadership is not telling us their plan other to establish credibility again. Doesn’t help that they won’t talk to us and update us at least quarterly. Does that seem unreasonable? Our future looks bright to me either way… our return on our investment is good either way. Who could analyze financially what is better? Please look at the numbers if that’s your thing and give an opinion.